Tuesday, July 27, 2021
All countries COVID-19 Cases
195,792,528
Total confirmed cases
Updated on July 27, 2021 8:24 PM

NIH begins clinical trial testing COVID-19 vaccine in pregnant women By Reuters

Must Read
- Advertisement -
Writer
© Reuters. FILE PHOTO: A woman receives a COVID-19 vaccine at a clinic in Philadelphia, Pennsylvania, USA, May 18, 2021. REUTERS / Hannah Beier / File Photo

By Dania Nadeem

(Reuters) – The US National Institutes of Health (NIH) said on Wednesday they had begun a study to assess the immune responses generated by COVID-19 vaccines in pregnant or postpartum women.

Pregnant women are at increased risk of complications, such as premature delivery, high blood pressure with risk of organ failure, the need for intensive care and possible death, according to the NIH.

A February research study in Israel showed that antibodies were detected in all 20 women given the doses of the Pfizer / BioNTech vaccine during their third trimester of pregnancy and also in their newborns.

Pfizer (NYSE 🙂 and BioNTech in February began a separate trial, with 4,000 international volunteers, evaluating the safety and effectiveness of their COVID-19 vaccine in healthy pregnant women.

The NIH study, MOMI-VAX, will measure the development and durability of coronavirus antibodies in vaccinated women during pregnancy or the first two months postpartum.

The researchers will evaluate the safety of the vaccine and will also evaluate whether vaccinated pregnant women transmit protection to their babies through the placenta or breast milk.

Many pregnant women in the United States have already received the COVID-19 vaccine available under authorization for emergency use.

“The results of this study will fill in the gaps in our knowledge and help inform policy recommendations and personal decision making about COVID-19 vaccination during pregnancy,” said Dr. Anthony Fauci, director of the National Allergy Institute. and Infectious Diseases (NIAID). NIAID is funding the study.

The trial will enroll up to 750 pregnant women and 250 postpartum women within two months of delivery, who have already received or will receive a COVID-19 vaccine cleared by the US Food and Drug Administration (FDA).

The FDA has authorized vaccines of Modern (NASDAQ :), Pfizer-BioNTech and Johnson & Johnson (NYSE 🙂 for emergency use.

Disclaimer: Fusion Media I would like to remind you that the data contained in this website is not necessarily real time or accurate. All CFDs (stocks, indices, futures) and Forex prices are not provided by exchanges but by market makers, so the prices may not be accurate and may differ from the actual market price, which means that prices are indicative and not appropriate for commercial purposes. Therefore, Fusion Media assumes no responsibility for any business losses you may incur as a result of the use of this data.

Fusion Media or anyone involved with Fusion Media will not accept any responsibility for loss or damage as a result of reliance on information, including data, quotes, charts, and buy / sell signals contained on this website. Be fully informed about the risks and costs associated with trading the financial markets, it is one of the riskiest forms of investment possible.

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

SUGGESTED NEWS
- Advertisement -
Latest News

A booming digital health market and an elusive trifecta

The markets are full of the latest Rock Health Report on funding for digital health in the first half...
- Advertisement -

More Articles Like This

- Advertisement -